{
    "nctId": "NCT04756921",
    "briefTitle": "18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response",
    "officialTitle": "Pretreatment 18F-FDG Uptake Heterogeneity Predicts Response to Pyrotinib in Patients With Metastatic HER2-positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically confirmed HER2 positive breast cancer\n* Treated with Pyrotinib in the metastatic settings\n* Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine were included in this study\n\nExclusion Criteria:\n\n* Incomplete medical history\n* Loss of follow up",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}